Haitao Hu

University of Texas Medical Branch
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (6)

Epigenetic suppression and durable silencing of HIV represent a promising strategy to achieve ART-free remission, consistent with the “block and lock” HIV cure paradigm. BRD4 is a host epigenetic reader and plays a critical role in HIV transcriptional regulation. We previously identified ZL0580, a first-in-class BRD4-selective small molecule distinct from the pan-BET inhibitor JQ1, which induces HIV epigenetic suppression. However, detailed molecular mechanisms, pharmacokinetics (PK), and in vivo HIV-suppressive efficacy of ZL0580 remain undefined. Here, we show that ZL0580 selectively targets BRD4 bromodomain 1 (BD1) through interaction with a key glutamic acid residue (E151), as determined by structural modeling and mutagenesis. Transcriptomic profiling by RNA-seq reveals that ZL0580 and JQ1 induce opposing gene expression programs, consistent with their distinct effects on HIV proviral transcription and latency. In a humanized mouse model of HIV infection, ZL0580 monotherapy, or in combination with ART, potently suppressed active HIV replication, reducing the plasma viremia to nearly undetectable levels, and delayed viral rebound following treatment interruption. Collectively, these findings establish ZL0580 as an epigenetic suppressor of HIV in vivo and provide proof-of-concept for its potential as a “block and lock” HIV cure candidate, warranting further optimization and development.

Year:

2025

Monoclonal antibodies (mAbs) have been developed as effective biological countermeasures against a range of human diseases. The high cost of antibody production and manufacturing limits its clinical application and widespread use. The mRNA-lipid nanoparticle (mRNA-LNP) is a versatile platform for development of vaccines and protein-replacement therapeutics. Since the COVID-19 pandemic, a number of neutralizing mAbs against SARS-CoV-2 have been identified with several being used clinically under emergency authorization. Herein, we report the design and generation of mRNA-LNPs expressing two SARS-CoV-2 neutralizing mAbs, 76E1 and LY1404, which respectively target the viral spike protein’s fusion peptide (FP) epitope within the S2 subunit and the receptor-binding domain (RBD) within the S1 subunit. We show a single intramuscular administration of mRNA-LNPs results in efficient LY1404 and 76E1 mAb production in mice which is sustained for 7-14 days. Further, we evaluate the protective efficacy of mRNA-LNP formulations encoding the two antibodies in mouse and hamster models challenged with different SARS-CoV-2 viral strains. The data demonstrate that a single administration of mRNA-LNP encoding the more broadly neutralizing antibody 76E1 confers significant protection against the immune-evasive SARS-CoV-2 Omicron variant BQ.1 in both the upper and lower respiratory tract of the hamsters, indicating its potential impact on limiting both viral disease and viral acquisition. Together, our study highlights the potential of the mRNA-LNP platform to deliver therapeutic antibodies for rapid prevention or treatment of pathogenic infections.

Year:

2025

Clostridioides difficile infection (CDI) is an urgent public health threat with limited preventative options. In this work, we developed a messenger RNA (mRNA)–lipid nanoparticle (LNP) vaccine targeting C. difficile toxins and virulence factors. This multivalent vaccine elicited robust and long-lived systemic and mucosal antigen-specific humoral and cellular immune responses across animal models, independent of changes to the intestinal microbiota. Vaccination protected mice from lethal CDI in both primary and recurrent infection models, and inclusion of non-toxin cellular and spore antigens improved decolonization of toxigenic C. difficile from the gastrointestinal tract. Our studies demonstrate mRNA-LNP vaccine technology as a promising platform for the development of novel C. difficile therapeutics with potential for limiting acute disease and promoting bacterial decolonization.

Year:

2024

While first-generation, spike (S)-based COVID-19 vaccines were effective against early SARS-CoV-2 strains, the rapid evolution of novel Omicron subvariants have substantially reduced vaccine efficacy. As such, broadly protective vaccines against SARS-CoV-2 are needed to prevent future viral emergence. In addition, it remains less clear whether peripheral immunization, especially with mRNA vaccines, elicits effective respiratory immunity. Our group has developed a nucleoside-modified mRNA vaccine expressing the nucleocapsid (N) protein of the ancestral SARS-CoV-2 virus and has tested its use in combination with the S-based mRNA vaccine (mRNA-S). In this study, we examined efficacy of mRNA-N alone or in combination with mRNA-S (mRNA-S+N) against more immune evasive Omicron variants in hamsters. Our data show that mRNA-N alone induces a modest but significant protection against BA.5 and that dual mRNA-S+N vaccination confers complete protection against both BA.5 and BQ.1, preventing detection of virus in the hamster lungs. Analysis of respiratory immune response in mice shows that intramuscular mRNA-S+N immunization effectively induces respiratory S- and N-specific T cell responses in the lungs and in bronchoalveolar lavage (BAL), as well as antigen-specific binding IgG in BAL. Together, our data further support mRNA-S+N as a potential pan-COVID-19 vaccine for broad protection against current and emerging SARS-CoV-2 variants.

Year:

2024

A broadly protective vaccine for COVID-19 is needed to end the pandemic and to prevent its future recurrence. While the first-generation, spike-based vaccines are effective against early SARS-CoV-2 strains, the convergent evolution of the new Omicron variants with rapid spike mutations have substantively reduced vaccine efficacy. Another important question is whether intramuscular immunization, especially with mRNA vaccines, elicits effective respiratory immunity. Our group has developed a nucleoside-modified mRNA vaccine expressing nucleocapsid (N) protein of ancestral SARS-CoV-2 virus and tested its use in combination with spike mRNA vaccine (mRNA-S). In this study, we examined efficacy of mRNA-N alone or in combination with mRNA-S (mRNA-S+N) against newer Omicron variants in hamsters. Our study shows that mRNA-N alone induces a modest, but significant protection against both Omicron BA.5 and BQ.1, and that dual mRNA-S+N vaccination confers complete protection against both variants, preventing detection of virus in the hamster lungs. Further analysis of respiratory immune response in mice shows that intramuscular immunization with the dual mRNA-S+N vaccine induces strong respiratory antigen-specific T cell responses in the lungs and in bronchoalveolar lavage (BAL), as well as antigen-specific binding IgG in BAL. Together, our data support mRNA-S+N as a potential pan-COVID-19 vaccine for broad protection against current and emerging SARS-CoV-2 variants. A broadly protective vaccine for COVID-19 is needed to end the pandemic and to prevent its future recurrence. While the first-generation, spike-based vaccines are effective against early SARS-CoV-2 strains, the convergent evolution of the new Omicron variants with rapid spike mutations have substantively reduced vaccine efficacy. Another important question is whether intramuscular immunization, especially with mRNA vaccines, elicits effective respiratory immunity. Our group has developed a nucleoside-modified mRNA vaccine expressing nucleocapsid (N) protein of ancestral SARS-CoV-2 virus and tested its use in combination with spike mRNA vaccine (mRNA-S). In this study, we examined efficacy of mRNA-N alone or in combination with mRNA-S (mRNA-S+N) against newer Omicron variants in hamsters. Our study shows that mRNA-N alone induces a modest, but significant protection against both Omicron BA.5 and BQ.1, and that dual mRNA-S+N vaccination confers complete protection against both variants, preventing detection of virus in the hamster lungs. Further analysis of respiratory immune response in mice shows that intramuscular immunization with the dual mRNA-S+N vaccine induces strong respiratory antigen-specific T cell responses in the lungs and in bronchoalveolar lavage (BAL), as well as antigen-specific binding IgG in BAL. Together, our data support mRNA-S+N as a potential pan-COVID-19 vaccine for broad protection against current and emerging SARS-CoV-2 variants.

Year:

2024

Emergence of SARS-CoV-2 variants of concern (VOCs), including the highly transmissible Omicron and Delta strains, has posed constant challenges to the current COVID-19 vaccines that principally target the viral spike protein (S). Here, we report a nucleoside-modified messenger RNA (mRNA) vaccine that expresses the more conserved viral nucleoprotein (mRNA-N) and show that mRNA-N vaccination alone can induce modest control of SARS-CoV-2. Critically, combining mRNA-N with the clinically proven S-expressing mRNA vaccine (mRNA-S+N) induced robust protection against both Delta and Omicron variants. In the hamster models of SARS-CoV-2 VOC challenge, we demonstrated that, compared to mRNA-S alone, combination mRNA-S+N vaccination not only induced more robust control of the Delta and Omicron variants in the lungs but also provided enhanced protection in the upper respiratory tract. In vivo CD8 + T cell depletion suggested a potential role for CD8 + T cells in protection conferred by mRNA-S+N vaccination. Antigen-specific immune analyses indicated that N-specific immunity, as well as augmented S-specific immunity, was associated with enhanced protection elicited by the combination mRNA vaccination. Our findings suggest that combined mRNA-S+N vaccination is an effective approach for promoting broad protection against SARS-CoV-2 variants.

Year:

2022

Collaborators (13)

Mark A. Sellmyer

University of Pennsylvania

UNITED STATES
View details

Ahmed Magdi Moustafa

Assistant Professor of Pediatrics

University of Pennsylvania Perelman School of Medicine

UNITED STATES
View details

Marc Lavertu

Associate Professor

Polytechnique Montréal

CANADA
View details

Robert Mach

Britton Chance Professor

University of Pennsylvania

UNITED STATES
View details

Mohamad-Gabriel Alameh

Assistant Professor

Children's Hospital of Philadelphia

UNITED STATES
View details

Paul Planet

Assistant Professor

University of Pennsylvania

UNITED STATES
View details

Joseph Zackular

Associate Professor

Children's Hospital of Philadelphia

UNITED STATES
View details

drew weissman

Professor

University of Pennsylvania

UNITED STATES
View details

Michael Abt

Associate Professor

University of Pennsylvania

UNITED STATES
View details

Yuejin Liang

Associate Director of Flow Cytometry and Cell Sorting Core Facility

University of Texas Medical Branch

UNITED STATES
View details

Kyle Bittinger

Children's Hospital of Philadelphia

UNITED STATES
View details

Scott C. Weaver

Chair

University of Texas Medical Branch

UNITED STATES
View details

Kenneth Plante

Associate Director of the WRCEVA, Assistant Professor

University of Texas Medical Branch

UNITED STATES
View details